Acadia Pharmaceuticals

Executive Director, Commercial Data Strategy and Analytics

Conshohocken, Pennsylvania, United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biopharmaceutical, PharmaceuticalsIndustries

Requirements

The Executive Director, Commercial Data Strategy and Analytics should have a strong track record in building and scaling global commercial data ecosystems. Experience in the biopharmaceutical industry, specifically with NASH therapeutics like Rezdiffra, is essential. The role requires oversight of commercial analytics and data management teams, with a need for cross-functional insight generation across U.S. and ex-U.S. markets. Expertise in integrating specialty pharmacy, hub, claims, CRM, payer, and EMR data is crucial, along with a deep understanding of commercial data governance, quality standards, and lifecycle management. Proficiency in advanced analytics, AI, and data science capabilities, including predictive analytics and next-best-action engines, is necessary. Experience managing relationships with analytics vendors and data aggregators such as IQVIA, Symphony, Veeva, and Snowflake is also required.

Responsibilities

The Executive Director will define and lead a multi-year commercial data and analytics vision and strategy, developing a roadmap to evolve commercial data capabilities, tools, and infrastructure. They will identify and prioritize high-value commercial analytics capabilities to support Rezdiffra's growth and champion advanced AI and data science capabilities. This role involves owning the global commercial data strategy, ensuring scalable integration of various data sources, and partnering with IT on commercial data governance, quality standards, and best practices. The Executive Director will support the development and adoption of enterprise predictive-analytics products, translate their outputs into commercial action plans, and own BI development of key dashboards. They will oversee the delivery of integrated insights and analytics across global and U.S. markets, establish a unified global KPI framework, and manage the commercial analytics team, including brand analytics leadership. Additionally, the role involves managing end-to-end visibility into the patient experience through data integration, supporting brand teams with actionable insights, building and mentoring a high-performing analytics team, and leading relationships with key analytics vendors and data aggregators.

Skills

Data Strategy
Analytics
AI
Data Science
Predictive Analytics
CRM
Specialty Pharmacy Data
Claims Data
EMR Data
Commercial Data Management
Leadership

Acadia Pharmaceuticals

Develops therapies for neurological disorders

About Acadia Pharmaceuticals

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these disorders while also promoting diversity, equity, and inclusion within their operations.

Dallas, TexasHeadquarters
1993Year Founded
$813.4MTotal Funding
ACQUISITIONCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Holidays
Paid Sick Leave
Paid Parental Leave
Tuition Reimbursement

Risks

Increased competition in CNS drug market may impact Acadia's market share.
Potential clinical trial delays could affect drug approval timelines.
Dependence on partnerships poses risks if collaborations face challenges or dissolve.

Differentiation

Acadia focuses on CNS disorders with unmet medical needs, like Parkinson's and Rett syndrome.
The company has a strong R&D foundation, developing innovative small molecule drugs.
Acadia's strategic partnerships enhance its research capabilities and market reach.

Upsides

Acadia's collaboration with Saniona expands its portfolio with SAN711 for neurological disorders.
Health Canada's approval of Daybue boosts Acadia's presence in the Canadian market.
The rise of personalized medicine aligns with Acadia's targeted therapy approach.

Land your dream remote job 3x faster with AI